Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 16  |  Issue : 4  |  Page : 919-921

Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib

1 Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Gunma University Hospital, Gunma, Japan
2 Department of Respiratory Medicine, Hidaka Hospital, Gunma, Japan
3 Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan
4 Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Takasaki, Gunma, Japan

Correspondence Address:
Kyoichi Kaira
Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, Showa-Machi, Maebashi, Gunma 371-8511
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_985_15

Rights and Permissions

An 84-year-old male had a recurrence after surgical resection against Stage IIIA pulmonary adenocarcinoma and was treated with crizotinib due to harboring the anaplastic lymphoma kinase fusion gene. The patient exhibited crizotinib-induced interstitial lung disease (ILD), and alectinib was administered because of progressive disease. However, ILD appeared in both lungs again after alectinib treatment. This is the first case of ILD, resulting from alectinib administration after crizotinib-induced ILD. We should pay careful attention to patients who are treated with alectinib after crizotinib-induced ILD.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded245    
    Comments [Add]    

Recommend this journal